Ovid Therapeutics Inc.

DB:1OT Stock Report

Market Cap: €17.9m

Ovid Therapeutics Management

Management criteria checks 2/4

Ovid Therapeutics' CEO is Jeremy Levin, appointed in Mar 2015, has a tenure of 10.17 years. total yearly compensation is $2.77M, comprised of 22.5% salary and 77.5% bonuses, including company stock and options. directly owns 5.14% of the company’s shares, worth €919.33K. The average tenure of the management team and the board of directors is 2.3 years and 3.8 years respectively.

Key information

Jeremy Levin

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage22.54%
CEO tenure10.2yrs
CEO ownership5.1%
Management average tenure2.3yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jeremy Levin's remuneration changed compared to Ovid Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$24m

Dec 31 2024US$3mUS$625k

-US$26m

Sep 30 2024n/an/a

-US$33m

Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$2mUS$597k

-US$51m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$3mUS$607k

-US$54m

Sep 30 2022n/an/a

-US$68m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$847kUS$584k

US$120m

Sep 30 2021n/an/a

US$123m

Jun 30 2021n/an/a

US$117m

Mar 31 2021n/an/a

US$110m

Dec 31 2020US$2mUS$560k

-US$81m

Sep 30 2020n/an/a

-US$76m

Jun 30 2020n/an/a

-US$76m

Mar 31 2020n/an/a

-US$67m

Dec 31 2019US$3mUS$530k

-US$60m

Sep 30 2019n/an/a

-US$56m

Jun 30 2019n/an/a

-US$53m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$3mUS$530k

-US$52m

Compensation vs Market: Jeremy's total compensation ($USD2.77M) is above average for companies of similar size in the German market ($USD499.93K).

Compensation vs Earnings: Jeremy's compensation has increased whilst the company is unprofitable.

CEO

Jeremy Levin (71 yo)

10.2yrs
Tenure
US$2,774,102
Compensation

Dr. Jeremy Max Levin, M.D., Ph D., BA Zoology, DPhil, MB BChir, serves as Director of Graviton BioScience Corporation from May 2023. He is Member of Advisory Board at New Rhein Healthcare Investors LLC.He...

Leadership Team

NamePositionTenureCompensationOwnership
Jeremy Levin
CEO & Chairman10.2yrsUS$2.77m5.14%
€ 919.3k
Margaret Alexander
President & COOless than a yearUS$1.66m0.10%
€ 18.5k
Jeffrey Rona
Chief Business and Financial Officer3.9yrsUS$1.52m0.13%
€ 23.1k
Dirk Haasner
Senior Vice President of Global Manufacturing & CMC QA9.2yrsUS$1.18mno data
Julia Tsai
Senior Vice President of Clinical Development3.8yrsno datano data
Toshiya Nishi
Head of Epilepsy Research2.3yrsno datano data
Zhong Zhong
Chief Scientific Officer1.9yrsno datano data
Manal Morsy
Chief Regulatory Officerless than a yearno datano data
Victoria Fort
Senior Vice President of Corporate Affairs & Corporate Strategyless than a yearno datano data
Tom Parry
Vice President of Research and Early Developmentno datano datano data
Garret Bonney
Investor Relations Officerno datano datano data
2.3yrs
Average Tenure
56yo
Average Age

Experienced Management: 1OT's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jeremy Levin
CEO & Chairman11.1yrsUS$2.77m5.14%
€ 919.3k
Robert S. Langer
Chairman of the Scientific & Clinical Advisory Board4.1yrsno datano data
Barbara Duncan
Independent Director7.9yrsUS$210.56k0%
€ 0
Bart Friedman
Lead Independent Director9.5yrsUS$228.06k0%
€ 0
Jacqueline A. French
Member of Scientific & Clinical Advisory Board8.3yrsno datano data
Karen Bernstein
Independent Director9.7yrsUS$215.56k0.028%
€ 5.0k
Raman Sankar
Member of Scientific Advisory Boardless than a yearno datano data
Kevin Fitzgerald
Independent Director3.6yrsUS$195.56k0%
€ 0
Jeffrey Noebels
Member of Scientific Advisory Boardless than a yearno datano data
Imad Najm
Member of Scientific Advisory Boardless than a yearno datano data
Jamie Maguire
Member of Scientific Advisory Boardless than a yearno datano data
Isam Awad
Member of Scientific Advisory Board1.3yrsno datano data
3.8yrs
Average Tenure
71yo
Average Age

Experienced Board: 1OT's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 19:46
End of Day Share Price 2025/05/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ovid Therapeutics Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Thomas ShraderBTIG
Jason ButlerCitizens JMP Securities, LLC